The National Medical Products Administration held an exchange meeting on the transformation and application of innovations in recombinant human collagen bio-materials

On June 18, the National Medical Products Administration held an exchange meeting on the transformation and application of innovations in recombinant human collagen bio-materials. Relevant units communicated face-to-face, in-depth understanding of the development status of recombinant human collagen innovative bio-materials, deployed and strengthened guidance for industrial development, accelerated the transformation of innovation achievements, and promoted the high-quality development of the medical device industry. Jiao Hong, director of the National Medical Products Administration, presided over the meeting and delivered a speech. Xu Jinghe, deputy director of the National Medical Products Administration, attended the meeting.

　　 The meeting heard the introduction of the research and transformation of the recombinant human collagen innovative bio-materials by the company. The Guangdong Provincial Food and Drug Administration and the Guangdong Transformation and Reform Comprehensive Demonstration Zone reported on their assistance to industrial development. The meeting fully affirmed the achievements made by enterprises and relevant departments of Guangdong Province in promoting the development and transformation of innovative bio-materials in my country. The meeting pointed out that the high-quality development of the medical device industry is inseparable from the support of scientific and technological innovation. The National Medical Products Administration has always paid close attention to the cutting-edge development of the pharmaceutical industry, continuously deepened the reform of the medical device review and approval system, and actively promoted scientific research on medical device supervision. Provide powerful guarantee for device R&D innovation and new technology promotion and application. Last year, the National Medical Products Administration listed medical scientific research on the supervision of new materials for medical devices as one of the first regulatory scientific research topics, laying a foundation for promoting the transformation of innovative achievements in the field of new materials.

The meeting emphasized that the National Medical Products Administration should seriously implement the important spirit of "strengthening scientific and technological innovation and continuously making breakthroughs in new infrastructure, new technologies, new materials, new equipment, new products, and new formats". "Scientific review" principle, strengthen communication with enterprises, establish a specific docking working mechanism, and establish new standards, new methods, and new tools for scientific supervision around new technologies, new materials, and new products. At the same time of control, we will make every effort to promote high-quality development of the industry.

The meeting also provided specific guidance on issues such as the nomenclature of recombinant human collagen innovative bio-materials, related standardization work, quality and safety evaluation methods, clinical evaluation requirements, and industrialization development, and made specific arrangements for accelerating the transformation of scientific research results and leading the development of new industries. Relevant comrades from the Device Registration Department of the National Medical Products Administration, the China Food and Drug Inspection Institute and the Medical Device Technology Evaluation Center of the State Bureau participated in the meeting.